Skip to main content
Journal cover image

Consensus recommendations for the use of novel antiretrovirals in persons with HIV who are heavily treatment-experienced and/or have multidrug-resistant HIV-1: Endorsed by the American Academy of HIV Medicine, American College of Clinical Pharmacy: An executive summary.

Publication ,  Journal Article
Cluck, DB; Chastain, DB; Murray, M; Durham, SH; Chahine, EB; Derrick, C; Dumond, JB; Hester, EK; Jeter, SB; Johnson, MD; Kilcrease, C; Poe, JB ...
Published in: Pharmacotherapy
May 2024

Treatment options are currently limited for persons with HIV-1 (PWH) who are heavily treatment-experienced and/or have multidrug-resistant HIV-1. Three agents have been approved by the U.S. Food and Drug Administration (FDA) since 2018, representing a significant advancement for this population: ibalizumab, fostemsavir, and lenacapavir. However, there is a paucity of recommendations endorsed by national and international guidelines describing the optimal use (e.g., selection and monitoring after initiation) of these novel antiretrovirals in this population. To address this gap, a modified Delphi technique was used to develop these consensus recommendations that establish a framework for initiating and managing ibalizumab, fostemsavir, or lenacapavir in PWH who are heavily treatment-experienced and/or have multidrug-resistant HIV-1. In addition, future areas of research are also identified and discussed in the main document.

Duke Scholars

Published In

Pharmacotherapy

DOI

EISSN

1875-9114

Publication Date

May 2024

Volume

44

Issue

5

Start / End Page

354 / 359

Location

United States

Related Subject Headings

  • United States
  • Practice Guidelines as Topic
  • Piperazines
  • Pharmacology & Pharmacy
  • Organophosphates
  • Humans
  • HIV-1
  • HIV Infections
  • Drug Resistance, Multiple, Viral
  • Delphi Technique
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Cluck, D. B., Chastain, D. B., Murray, M., Durham, S. H., Chahine, E. B., Derrick, C., … Short, W. R. (2024). Consensus recommendations for the use of novel antiretrovirals in persons with HIV who are heavily treatment-experienced and/or have multidrug-resistant HIV-1: Endorsed by the American Academy of HIV Medicine, American College of Clinical Pharmacy: An executive summary. Pharmacotherapy, 44(5), 354–359. https://doi.org/10.1002/phar.2913
Cluck, David B., Daniel B. Chastain, Milena Murray, Spencer H. Durham, Elias B. Chahine, Caroline Derrick, Julie B. Dumond, et al. “Consensus recommendations for the use of novel antiretrovirals in persons with HIV who are heavily treatment-experienced and/or have multidrug-resistant HIV-1: Endorsed by the American Academy of HIV Medicine, American College of Clinical Pharmacy: An executive summary.Pharmacotherapy 44, no. 5 (May 2024): 354–59. https://doi.org/10.1002/phar.2913.
Cluck DB, Chastain DB, Murray M, Durham SH, Chahine EB, Derrick C, Dumond JB, Hester EK, Jeter SB, Johnson MD, Kilcrease C, Kufel WD, Kwong J, Ladak AF, Patel N, Pérez SE, Poe JB, Bolch C, Thomas I, Asiago-Reddy E, Short WR. Consensus recommendations for the use of novel antiretrovirals in persons with HIV who are heavily treatment-experienced and/or have multidrug-resistant HIV-1: Endorsed by the American Academy of HIV Medicine, American College of Clinical Pharmacy: An executive summary. Pharmacotherapy. 2024 May;44(5):354–359.
Journal cover image

Published In

Pharmacotherapy

DOI

EISSN

1875-9114

Publication Date

May 2024

Volume

44

Issue

5

Start / End Page

354 / 359

Location

United States

Related Subject Headings

  • United States
  • Practice Guidelines as Topic
  • Piperazines
  • Pharmacology & Pharmacy
  • Organophosphates
  • Humans
  • HIV-1
  • HIV Infections
  • Drug Resistance, Multiple, Viral
  • Delphi Technique